Board of Directors
Timo Veromaa MD, PhD, eMBA, has been a Herantis board member since 2012 and chairman since April 2020. He is also the former executive chairman of Domainex Ltd and was the CEO and President of Biotie Therapies Corp., from 2005 until its acquisition by Acorda Therapeutics in 2016. He is also the Chairman of Finnish BioBanks FINBB from 2017 and was Chairman of Finnish Bioindustries FIB 2012- 2018. During the beginning of his career, he was Medical Director of Schering Ltd. in Finland, Senior Scientist and Project Director of Collagen Corp. and a Postdoctoral Fellow at Stanford University. Timo Veromaa has a PhD in immunology from the University of Turku and Special Competence in Pharmaceutical Medicine from the Finnish Medical Association.
Frans Wuite MD, MBA has been a Herantis Board member since 2014 and vice chairman since April 2020. He has a long international career with a track record of successfully commercializing and growing pharmaceutical and biotech businesses. Frans Wuite was CEO of Acesion Pharma ApS until 2020. Prior to this, he was CEO and President of Oncos Therapeutics Oy, COO of Warren Pharmaceuticals Inc, Co-founder and Board Director of Araim Pharmaceuticals Inc, and member of Amgen’s European management team, where he was in charge of establishing the anaemia franchise. Before Amgen, he was President of Pharmacia-Leiras BV, a joint venture for marketing products with novel dose delivery technologies for women’s healthcare in Europe. Frans is also a current board director of Healthcap VII GP SA and Nukute Oy
Jim (James) Phillips MD, MBA has been a board member of Herantis since 2014. He is currently CEO of PAION AG a commercial stage pharmaceutical company. Jim Phillips previous roles included CEO of Imevax GmbH, CEO for Midatech Pharma PLC, President of EUSA Pharma Europe (prior to its sale in 2012 to Jazz Pharma), and CEO & founder in Talisker Pharma (acquired by EUSA in 2006). Prior to that he worked at Johnson & Johnson and Novartis as a senior executive in pharmaceutical development & commercialisation.
Aki Prihti has been a Herantis Board member since 2014. Currently he is CEO of Aplagon Oy and CFO and board member of Medtentia International Ltd Oy. He was previously the chairman of Laurantis Pharma Ltd from 2010– 2014. Aki Prihti is one of the founding partners of the venture fund management company Inveni Capital and currently serves as a board member in Dassiet Oy and Rokote Laboratories Finland Oy. Prior to transitioning to life science venture capital, he worked in the corporate finance arm of Salomon Brothers in London.
Mats Thorén, has been a Herantis Board member since 2020. Currently CEO of Vixco Capital. He was one of the founding partners of Catella Healthcare, an investment firm in the Healthcare business. Mats Thorén has been a first-ranked equity research analyst in Sweden with SEB and the Head of Swedish Healthcare with SHB Markets Corporate Finance. He currently serves on the Board of Arcoma AB, Xbrane Biopharma AB and FluoGuide A/S.
Hilde Furberg was elected to the Herantis Pharma board in 2021. She brings 30+ years of experience in sales, marketing, strategy and management in Pharma / Biotech, most recently as European Head of Rare Disease Europe/ General Manager and Senior Vice President Rare Diseases EMEA at Genzyme/ Sanofi Genzyme. Hilde was also the General Manager at Pharmalink and Baxter Healthcare. Since 2005, Hilde has also worked as non-executive director and Board member of Probi, Pronova, Clavis, Bergenbio, Algeta, Tappin and Combigene, and was CoB at Blueprint Genetics. She holds a Master of Science from the University of Oslo. She is currently an industrial advisor to Investinor and Board member of Bio-me, OncoZenge, PCI Biotech, Calliditas and Sedana Medical.